This was a multi-center , randomized , double-blind , placebo-controlled , 16-week study comparing alogliptin ( ALO , 25 mg , 1/d ) versus placebo ( PLA ) as monotherapy ( A ) , add-on to metformin ( B ) or add-on to pioglitazone metformin ( C ) .